Yael Margolin

Denali Ventures LLC (Denali) was a private Israeli venture capital firm which was founded in 1998 with the backing of private US investors, and ceased operating in 2008. Denali focused exclusively on investments in life science and health care technology companies. Located in Herzlia, the firm invested in Israel while sueing a global approach towards product and corporate development.

Collgard Biopharmaceuticals, the tissue therapeutics company, is developing drug treatments that target disease progression by directly influencing the tissue regeneration process. Central to Collgard's novel approach is its lead drug candidate, Tempostatin (Halofuginone hydrobromide). Tempostatin is a multi-indication, small-molecule drug candidate that has been identified by the company as influencing a 'master switch' in the body's tissue repair process. As a potent and selective regulator of stromal cell activation, cell migration and excessive collagen type I synthesis, Tempostatin makes it possible to harness and direct the tissue repair process for treating diseases acting at the tissue level. Collgard is developing therapeutic solutions for several clinical indications with significant unmet clinical needs. These solutions are based on highly specific control of the tissue repair process. Current programs target the following indications vascular restenosis, end-organ fibrosis, selected cancers and dermal fibroproliferative disorders. Tempostatin holds exceptional promise based on addressing a fundamental underlying pathological process that is not accessible to other current therapeutic approaches. In developing Tempostatin, Collgard seeks to offer novel therapeutic solutions as well as extend the effectiveness of existing therapies. Founded in 1996, Collgard Biopharmaceuticals is a privately held, clinical stage company, led by a global team of medical and drug development experts based in Atlanta and Tel Aviv. Scientific and clinical collaborators include The Mayo Clinic, the U.S. NCI, the EORTC, and Harvard Medical School. Collgard was founded by Medica Venture Partners. Additional investors include Mayo Medical Ventures, Denali Ventures, Yozma Group, and Comsor.

Teva Pharmaceuticals USA, Inc. engages in the manufacturing and marketing of generic pharmaceuticals. The firm also provides medical affairs, quality plus safety and trade partner services. The company was founded in 1985 and is headquartered in Parsippany, NJ.

Ramot at Tel Aviv University Ltd. operates as a technology transfer company of Tel Aviv University (TAU). It provides legal and commercial frameworks for inventions made by TAU faculty, students, and researchers. The firm licenses the university's intellectual property to third parties through agreements; facilitates collaborative research partnerships between business partners and TAU researchers; establishes a company; and forms joint ventures that promote TAU technologies. The company was founded in 1973 and is headquartered in Tel Aviv, Israel.

Part of Gamida Cell Ltd., Gamida Cell, Inc. develops cellular and immune therapeutics. The company is based in Medfield, MA. The CEO of the company is Julian Adams.